[Hangzhou Sunway Biotech: Enoglutide Can Reduce Weight By More Than 15% And May Be Approved As Early As Early 2026] Hangzhou Sunway Biotech Co., Ltd. Said That Its Drug Enoglutide Reduced Weight By More Than 15% After 48 Weeks Of Taking It At The Highest Dose. Pan Hai, The Company's CEO, Said That Although The Trial Did Not Directly Compare Enoglutide With Existing Drugs, The Results Were Very Similar To Those Of Eli Lilly's Zepbound In Previous Chinese Studies. He Said That Enoglutide Is A Once-weekly Injection That Is Currently Under Regulatory Review In China For The Treatment Of Obesity And Diabetes And May Be Approved As Early As Early 2026. Sunway Biotech Is In Early Talks With Potential Partners To Develop The Drug Overseas

Quick Access to 7x24

Quick Access to More Editor-selected Real-time News

Exclusive video for free

Live Learn project team is dedicated to create exclusive videos

Real-time Quotes

View more faster market quotes

More comprehensive macro data and economic indicators

Members have access to entire historical data, guests can only view the last 4 years

Member-only Database

Comprehensive forex, commodity, and equity market data